TCJL37
TCJL37 is a potent, selective, and orally bioavailable TYK2 inhibitor with a Ki of 1.6 nM. TCJL37 can be used for the research of inflammatory bowel diseases (IBD) [1].
Product Specifications
CAS Number
[1258294-34-6]
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/tcjl37.html
Purity
99.89
Solubility
DMSO : 175 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC(NC([C@@H]2[C@H](F)C2)=O)=NC=C1)C3=C(F)C=C(C#N)C=C3Cl
Molecular Formula
C17H11ClF2N4O2
Molecular Weight
376.74
Precautions
H302, H315, H319
References & Citations
[1]Jun Liang, et al. Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors. J Med Chem. 2013 Jun 13;56 (11) :4521-36.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Tyk2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15373972 1 Vial
Lentiviral human ABLIM3 sgRNA gene knockout kit - Lentiviral human ABLIM3 sgRNA gene knockout kit (100)
Ask
View Details 
